A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

2023-503547-33-00 Human pharmacology (Phase I) - Other Ended

Start 12 Jul 2023 · End 21 Jan 2025 · Status Ended · 1 EU/EEA countries · 4 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 60
Countries 1
Sites 4

Advanced solid tumors

Key facts

Sponsor
Bayer AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
12 Jul 2023 → 21 Jan 2025
Decision date (initial)
2024-05-03
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-503547-33-00
EudraCT number
2020-003547-28
ClinicalTrials.gov
NCT04999202

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065147 Malignant solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bayer AG

Sponsor organisation
Bayer AG
Address
Kaiser-Wilhelm-Allee 1, Wiesdorf Wiesdorf
City
Leverkusen
Postcode
51373
Country
Germany

Scientific contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Public contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 15 4
Rest of world
United Kingdom, Singapore, United States
45

Investigational sites

Italy

4 sites · Ended
Humanitas Research Hospital
Oncologia Medica ed Ematologia, Via Alessandro Manzoni 56, 20089, Rozzano
European Institute Of Oncology S.r.l.
Sviluppo Nuovi Farmaci per Terapie Innovative, Via Giuseppe Ripamonti 435, 20141, Milan
Fondazione IRCCS Istituto Nazionale Dei Tumori
Oncologia Medica 1, Via Giacomo Venezian 1, 20133, Milan
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Sperimentazioni Cliniche, Via Mariano Semmola 52, 80131, Naples

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2023-07-12 2025-01-20 2023-07-20 2023-11-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-02 Italy Acceptable
2024-05-03
2024-05-03
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-06-13 Italy Acceptable
2024-05-03
2024-06-13
3 SUBSTANTIAL MODIFICATION SM-1 2024-11-28 Italy Acceptable
2025-01-22
2025-01-24